Information Provided By: 
Fly News Breaks for June 14, 2019
MYGN
Jun 14, 2019 | 06:21 EDT
Barclays analyst Jack Meehan lowered his price target for Myriad Genetics to $18 from $20 and keeps an Underweight rating on the shares. The analyst now sees a probability of GeneSight non-coverage of 35% versus his prior view of 20%. He believes several Medicare Administrative Contractors hosting on June 26 a multi-jurisdictional Contractor Advisory Committee meeting to discuss pharmacogenomics in psychiatry raises the risk of GeneSight's "downside case."
News For MYGN From the Last 2 Days
There are no results for your query MYGN
